236 related articles for article (PubMed ID: 23321674)
1. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.
Thiem S; Pierce TP; Palmieri M; Putoczki TL; Buchert M; Preaudet A; Farid RO; Love C; Catimel B; Lei Z; Rozen S; Gopalakrishnan V; Schaper F; Hallek M; Boussioutas A; Tan P; Jarnicki A; Ernst M
J Clin Invest; 2013 Feb; 123(2):767-81. PubMed ID: 23321674
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.
Stuart E; Buchert M; Putoczki T; Thiem S; Farid R; Elzer J; Huszar D; Waring PM; Phesse TJ; Ernst M
Mol Cancer Ther; 2014 Feb; 13(2):468-74. PubMed ID: 24398427
[TBL] [Abstract][Full Text] [Related]
3. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.
Ernst M; Najdovska M; Grail D; Lundgren-May T; Buchert M; Tye H; Matthews VB; Armes J; Bhathal PS; Hughes NR; Marcusson EG; Karras JG; Na S; Sedgwick JD; Hertzog PJ; Jenkins BJ
J Clin Invest; 2008 May; 118(5):1727-38. PubMed ID: 18431520
[TBL] [Abstract][Full Text] [Related]
4. Activation of the mTORC1 and STAT3 pathways promotes the malignant transformation of colitis in mice.
He Z; He X; Chen Z; Ke J; He X; Yuan R; Cai Z; Chen X; Wu X; Lan P
Oncol Rep; 2014 Nov; 32(5):1873-80. PubMed ID: 25174408
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.
Fujishita T; Aoki K; Lane HA; Aoki M; Taketo MM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13544-9. PubMed ID: 18768809
[TBL] [Abstract][Full Text] [Related]
6. The role of mTORC1 pathway in intestinal tumorigenesis.
Fujishita T; Aoki M; Taketo MM
Cell Cycle; 2009 Nov; 8(22):3684-7. PubMed ID: 19855161
[TBL] [Abstract][Full Text] [Related]
7. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA
Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613
[TBL] [Abstract][Full Text] [Related]
8. Repression of Mammalian Target of Rapamycin Complex 1 Inhibits Intestinal Regeneration in Acute Inflammatory Bowel Disease Models.
Guan Y; Zhang L; Li X; Zhang X; Liu S; Gao N; Li L; Gao G; Wei G; Chen Z; Zheng Y; Ma X; Siwko S; Chen JL; Liu M; Li D
J Immunol; 2015 Jul; 195(1):339-46. PubMed ID: 26026060
[TBL] [Abstract][Full Text] [Related]
9. Repurposing the selective estrogen receptor modulator
Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
[TBL] [Abstract][Full Text] [Related]
10. Stat3: linking inflammation to (gastrointestinal) tumourigenesis.
Ernst M; Putoczki TL
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):711-8. PubMed ID: 22211709
[TBL] [Abstract][Full Text] [Related]
11. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
Pollizzi K; Malinowska-Kolodziej I; Stumm M; Lane H; Kwiatkowski D
Mol Cancer; 2009 Jun; 8():38. PubMed ID: 19527517
[TBL] [Abstract][Full Text] [Related]
12. STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis.
Judd LM; Bredin K; Kalantzis A; Jenkins BJ; Ernst M; Giraud AS
Gastroenterology; 2006 Oct; 131(4):1073-85. PubMed ID: 17030178
[TBL] [Abstract][Full Text] [Related]
13. mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.
Li J; Liu J; Song J; Wang X; Weiss HL; Townsend CM; Gao T; Evers BM
Am J Physiol Cell Physiol; 2011 Jul; 301(1):C213-26. PubMed ID: 21508335
[TBL] [Abstract][Full Text] [Related]
14. Lewis lung carcinoma regulation of mechanical stretch-induced protein synthesis in cultured myotubes.
Gao S; Carson JA
Am J Physiol Cell Physiol; 2016 Jan; 310(1):C66-79. PubMed ID: 26491045
[TBL] [Abstract][Full Text] [Related]
15. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.
Umemura A; Park EJ; Taniguchi K; Lee JH; Shalapour S; Valasek MA; Aghajan M; Nakagawa H; Seki E; Hall MN; Karin M
Cell Metab; 2014 Jul; 20(1):133-44. PubMed ID: 24910242
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.
Guigon CJ; Fozzatti L; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2010 Jul; 31(7):1284-91. PubMed ID: 20299527
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A
Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.
Carracedo A; Ma L; Teruya-Feldstein J; Rojo F; Salmena L; Alimonti A; Egia A; Sasaki AT; Thomas G; Kozma SC; Papa A; Nardella C; Cantley LC; Baselga J; Pandolfi PP
J Clin Invest; 2008 Sep; 118(9):3065-74. PubMed ID: 18725988
[TBL] [Abstract][Full Text] [Related]
19. Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and regeneration.
Phesse TJ; Buchert M; Stuart E; Flanagan DJ; Faux M; Afshar-Sterle S; Walker F; Zhang HH; Nowell CJ; Jorissen R; Tan CW; Hirokawa Y; Eissmann MF; Poh AR; Malaterre J; Pearson HB; Kirsch DG; Provero P; Poli V; Ramsay RG; Sieber O; Burgess AW; Huszar D; Vincan E; Ernst M
Sci Signal; 2014 Sep; 7(345):ra92. PubMed ID: 25270258
[TBL] [Abstract][Full Text] [Related]
20. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.
Bollrath J; Phesse TJ; von Burstin VA; Putoczki T; Bennecke M; Bateman T; Nebelsiek T; Lundgren-May T; Canli O; Schwitalla S; Matthews V; Schmid RM; Kirchner T; Arkan MC; Ernst M; Greten FR
Cancer Cell; 2009 Feb; 15(2):91-102. PubMed ID: 19185844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
